Head-to-head · Value Score
Vitara RX vs TeleCareSpot
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, TeleCareSpot a 71. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameTeleCareSpot
#231 · Grade C · Watch List
Est. first month
From $299/mo (all doses, plus a separate fee, compounded)
Save ~78% vs brand-nameThe verdict
Vitara RX takes it on Value Score, 91 to 71 — an est. $99/mo first month, with no teaser step-up baked in. TeleCareSpot isn't out of it: Shoppers who want flat-priced, LegitScript-verified compounded semaglutide or tirzepatide with broad state coverage.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | TeleCareSpot |
|---|---|---|
| Value Score | 91 (A) | 71 (C) |
| Est. first month | $99/mo | From $299/mo (all doses, plus a separate fee, compounded) |
| Save vs brand-name | ~93% | ~78% |
| Semaglutide | $99/mo | From $299/mo (all doses, plus a separate fee, compounded) |
| Tirzepatide | $149/mo | $399/mo |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Flat — no step-up |
| Coverage | 49 states | 48 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
TeleCareSpot
TeleCareSpot is a telehealth weight-loss platform offering doctor-prescribed compounded GLP-1s with flat, all-inclusive monthly pricing: compounded semaglutide at $299/month and tirzepatide at $399/month…
Why it's a deal
- Flat, all-inclusive monthly pricing with no hidden fees — compounded semaglutide $299/month and tirzepatide $399/month, all doses included
- Verifiable LegitScript certification (seal ID 45936855) plus HIPAA compliance and licensed US physicians
- Multiple options: compounded semaglutide, tirzepatide, oral tirzepatide, and phentermine
- DNA-calibrated dosing option that tailors the GLP-1 dose to how you metabolize it
- Broad coverage in 47 states and DC, with free shipping and cancel-anytime plans
The fine print
- Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Not available in Alaska, Mississippi, or New Jersey
- The compounding pharmacy partner is not named
- A separate weight-loss consultation fee applies (credited toward your medication package if approved)
- Trustpilot rating and review counts (4.9, 14,000+) are self-stated on the site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to TeleCareSpot.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.